Lustgarten Foundation for Pancreatic Cancer Research

Newfound Mechanism Suggests Drug Combination Could Starve Pancreatic Cancer

Retrieved on: 
Monday, October 9, 2023
University of British Columbia, Doctor of Philosophy, Division, New York University Grossman School of Medicine, DON, Kimmelman, Glutaminase, MD, PDAC, Lustgarten Foundation for Pancreatic Cancer Research, Toxicity, Biochemistry, National Cancer Institute, Lung cancer, University, Survival, NYU Langone Health, Nature Cancer, Cancer, Therapy, Glutamine, Environment, Growth, Oxygen, ERK, Mouse, NYU, Pancreatic cancer, Neoplasm, Molecular biology, Enzyme, Radiation therapy, Medical imaging, Pharmaceutical industry

NEW YORK, Oct. 9, 2023 /PRNewswire/ -- A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.

Key Points: 
  • NEW YORK, Oct. 9, 2023 /PRNewswire/ -- A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.
  • Published online October 9 in Nature Cancer, the new study involves a drug designed to prevent pancreatic ductal adenocarcinoma (PDAC) cells from one such switch.
  • DON was designed to starve cancer cells by mimicking glutamine, which unlike glutaminase blockers, broadly inhibits all metabolic pathways that use glutamine.
  • In the current study, DRP-104 treatment alone decreased PDAC growth in mouse models of pancreatic cancer.

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer

Retrieved on: 
Wednesday, September 27, 2023
PDAC, DNA, Neoplasm, AACR, OS, Cancer, Pancreatic cancer, Oncology, ASCO, MRD, RFS, Research and development, Development, CD8, Lustgarten Foundation for Pancreatic Cancer Research, Patient, Risk, MSK, Memorial Sloan Kettering Cancer Center, Toxic epidermal necrolysis, CD4, Therapy, Death, Conference, Safety, Vaccine, Pharmaceutical industry, Medical imaging, Research

The data will be presented September 29th from 4:40pm – 6:40pm ET at the AACR Special Conference on Pancreatic Cancer in Boston, Massachusetts, taking place from September 27-30, 2023.

Key Points: 
  • The data will be presented September 29th from 4:40pm – 6:40pm ET at the AACR Special Conference on Pancreatic Cancer in Boston, Massachusetts, taking place from September 27-30, 2023.
  • We are encouraged by these early observations and look forward to continuing to follow and report additional clinical and biomarker data on the AMPLIFY-201 study.
  • Primary endpoints included safety and the recommended Phase 2 dose (RP2D) of Amph-CPG-7909, and the secondary endpoint included biomarker reduction/clearance.
  • No safety concerns were identified, and there were no dose limiting toxicities and no ≥ Grade 3 treatment related adverse events.

Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer

Retrieved on: 
Tuesday, September 5, 2023
KRAS, AACR, AMP, Neoplasm, Elicio Berriz, Pancreatic cancer, Cancer, Oncology, MRD, Lustgarten Foundation for Pancreatic Cancer Research, Patient, Pancreas, MSK, Memorial Sloan Kettering Cancer Center, Therapy, Conference, Safety, Pharmaceutical industry

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that additional data from the Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, will be presented in a poster presentation at the upcoming AACR Special Conference on Pancreatic Cancer taking place in Boston, Massachusetts from September 27-30, 2023.

Key Points: 
  • BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that additional data from the Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, will be presented in a poster presentation at the upcoming AACR Special Conference on Pancreatic Cancer taking place in Boston, Massachusetts from September 27-30, 2023.
  • These data are in addition to the interim data Elicio presented at the ASCO Annual Meeting earlier this year.
  • ELI-002 2P is a therapeutic cancer vaccine candidate that was designed with Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology to treat cancers driven by G12D and G12R mutations in KRAS.
  • AMPLIFY-201 is a multicenter Phase 1 trial assessing the safety, immunogenicity and antitumor activity of ELI-002 in patients with mutant KRAS-driven tumors who are at high risk for relapse due to detection of minimal residual disease (MRD) following standard surgery and chemotherapy.

RMS North America Chosen for TrustRadius 2023 Tech Cares Award

Retrieved on: 
Thursday, August 10, 2023
Environmental, Social and Governance (ESG), Data Management, Sustainability, Technology, Lodging, Professional Services, Philanthropy, Travel, Environment, Sports, Fund Raising, Outdoors, Vacation, Software, Other Philanthropy, Goodwill Industries, Goodwill, Pancreatic cancer, Rainforest Alliance, College, Tree, Rainforest, Clothing, National Forest, Woman, Meal, Grand America Hotels & Resorts, National Forest Foundation, CSR, Organization, Interface (computing), Climate change, RMS, Animal, DEI, Hunger, WWF, Lustgarten Foundation for Pancreatic Cancer Research, Female, Nursing, Pharmaceutical industry, Toy, Creative industries, Research

RMS North America , a leading provider of reservation and property management systems to the outdoor hospitality industry, has been recognized by TrustRadius as a 2023 Tech Cares Award winner , which celebrates organizations that have gone above and beyond to support their communities, employees, and environment.

Key Points: 
  • RMS North America , a leading provider of reservation and property management systems to the outdoor hospitality industry, has been recognized by TrustRadius as a 2023 Tech Cares Award winner , which celebrates organizations that have gone above and beyond to support their communities, employees, and environment.
  • Congratulations to RMS North America for being a shining example of excellence in the hospitality industry."
  • In addition to company sustainability initiatives, RMS North America offers property management and reservation software that empowers properties to establish their own sustainable practices, such as:
    “At RMS North America, we aim to continuously give back to our community, while supporting our valued employees' career and personal growth,” said Fred Dominioni, Chief Revenue Officer at RMS North America.
  • “We are thrilled to receive this recognition from TrustRadius and look forward to driving more initiatives that benefit the environment, our community, and our employees.”
    For more on the RMS North America team, careers, and past initiatives, visit: americas.rmscloud.com/our-team .

THE PANCREATIC CANCER ACTION NETWORK (PANCAN) ANNOUNCES NEW SCIENTIFIC AND MEDICAL ADVISORY BOARD LEADERS AND MEMBERS

Retrieved on: 
Tuesday, July 18, 2023
Memorial Sloan Kettering Cancer Center, Pancreatic cancer, Perelman School of Medicine at the University of Pennsylvania, University, MBA, Oncology, Research, Biomarker, Doctor of Philosophy, Associate, II, Cancer, Perelman Center for Advanced Medicine, Student, Pancreatic Cancer Action Network, MD, Patient, Physician, Nursing, Lustgarten Foundation for Pancreatic Cancer Research, Division, JD, MSK, University of Pennsylvania Health System, Knowledge, III, Caregiver, Chair, Pharmaceutical industry, Medicine

LOS ANGELES, July 18, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, proudly announces the addition of fourteen new members to its Scientific and Medical Advisory Board (SMAB), as well as the elevation of current SMAB members Eileen M. O'Reilly, MD, of Memorial Sloan Kettering Cancer Center (MSK) and Gregory Beatty, MD, PhD to the roles of Chair and Vice Chair, respectively.  

Key Points: 
  • PanCAN's SMAB is comprised of leading scientists, clinicians and healthcare professionals who specialize in pancreatic cancer from institutions across the United States.
  • "PanCAN is critically important to the field for many reasons, including its extensive outreach, scientific rigor, and support for the clinical and research pancreatic cancer community.
  • "This community is vital to the fight against pancreatic cancer, the sharing of knowledge, and the fostering of new ideas.
  • New members joining the PanCAN SMAB include:
    Additionally, members whose terms have ended are:

Lustgarten Foundation Announces the Appointment of Two New Board Members

Retrieved on: 
Thursday, July 13, 2023
Linda, Cloud, Pancreatic cancer, Society, Lustgarten Foundation for Pancreatic Cancer Research, Birmingham School of Law, University, American Surgical Association, Senior, Stanford University, PwC, Weak artificial intelligence, IBM/Google Cloud Computing University Initiative, Cancer, Dean, ...And You Will Know Us by the Trail of Dead, Research, Johns Hopkins School of Medicine, Doctor of Philosophy, UAB, Extrapyramidal system, National academy, Computation, National Academy of Medicine, Stanford University School of Medicine, Trustee, University of Minnesota Medical School, Memorial Sloan Kettering Cancer Center, MSK, FACS, Artificial intelligence, AI, Breast cancer, Pharmaceutical industry, Medical device, MD, Medicine

WOODBURY, N.Y., July 13, 2023 /PRNewswire-PRWeb/ -- The Lustgarten Foundation, the nation's largest private funder of pancreatic cancer research, today announced the appointment of two new board members: Selwyn M. Vickers, MD, FACS, and Scott Penberthy, PhD, MS. Dr. Vickers is an internationally recognized pancreatic cancer surgeon, pancreatic cancer researcher, and pioneer in health disparities research. Dr. Penberthy is a visionary engineering leader with extensive expertise in artificial intelligence (AI) and technology, specifically in the healthcare space.

Key Points: 
  • Selwyn M. Vickers, MD, FACS, and Scott Penberthy, PhD, MS, join the Lustgarten Foundation Board of Directors.
  • WOODBURY, N.Y., July 13, 2023 /PRNewswire-PRWeb/ -- The Lustgarten Foundation, the nation's largest private funder of pancreatic cancer research, today announced the appointment of two new board members: Selwyn M. Vickers, MD, FACS , and Scott Penberthy, PhD, MS .
  • "We are honored to welcome Dr. Vickers and Dr. Penberthy to the Lustgarten Foundation Board of Directors," said Linda Tantawi, CEO of the Lustgarten Foundation.
  • "At the Foundation, we firmly believe in the fundamental role of innovative and cutting-edge research in solving the complexities of pancreatic cancer.

RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board

Retrieved on: 
Tuesday, June 20, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, SAB, Pancreatic cancer, Interim, University, Pancreatic Cancer Action Network, Hematology, Schering-Plough, Cancer, Jim Valvano, UCSF Helen Diller Family Comprehensive Cancer Center, Lustgarten Foundation for Pancreatic Cancer Research, NIH Intramural Research Program, ASCO, EORTC, UCSF, Patient, Division, United States Air Force Scientific Advisory Board, Research, NCI, Armendariz v. Foundation Health Psychcare Services, Inc., Pharmaceutical industry, Medicine

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Company’s Scientific Advisory Board (SAB).

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Company’s Scientific Advisory Board (SAB).
  • She also serves as Chair of the NCCN Guidelines Panel on Pancreatic Cancer (since 2000), editor-in-chief of JNCCN, and on the ASCO Conquer Cancer Foundation Board.
  • Previously, Dr. Tempero has served on the ASCO Board of Directors, as ASCO President, and as a member of FDA’s Oncology Drug Advisory Committee.
  • She co-directed the AACR/ASCO Methods in Clinical Cancer Research and taught this course and similar courses in Europe and Australia.

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting

Retrieved on: 
Saturday, June 3, 2023
KRAS, Therapy, AMP, McCormick Place, Neoplasm, Aes, Elicio Berriz, Pancreatic cancer, Cancer, Toxicity, Oncology, Biomarker, ASCO, MRD, Research and development, Development, Phase 1, Literature, American Society of Clinical Oncology, Lustgarten Foundation for Pancreatic Cancer Research, Patient, Cytokine release syndrome, Lymph, Physician, Colorectal cancer, Risk, Immune system, Annual general meeting, MSK, Memorial Sloan Kettering Cancer Center, Toxic epidermal necrolysis, Safety, Society, Pancreatic tumor, Caregiver, Peptide, Pharmaceutical industry, Vaccine, Phosphorus, Research

This study evaluated ELI-002 2P, a 2-peptide formulation designed to treat cancers driven by G12D and G12R mutations in KRAS.

Key Points: 
  • This study evaluated ELI-002 2P, a 2-peptide formulation designed to treat cancers driven by G12D and G12R mutations in KRAS.
  • Responses were observed at all dose levels, with a high proportion of patients having tumor biomarker reduction including a subset with clearance.
  • Mutant KRAS drives 25% of solid human cancers with an overall poor prognosis and high relapse risk and limited therapeutic options.
  • Elicio has developed a broad spectrum 7-peptide formulation of ELI-002 currently being assessed in a Phase 1/2 study ( NCT05726864 ).

Ali Weiss Jewelry Empowers Giving Back with Charity Collaborations

Retrieved on: 
Wednesday, December 21, 2022
Diamond, Partnership, Friends, Jewellery, Plant, Jewish National Fund, Organization, Animal, Sale, Lustgarten Foundation for Pancreatic Cancer Research, North Shore Animal League America, Pancreatic cancer, Love, Pharmaceutical industry

Ali Weiss Jewelry extends their giving period throughout the year to support organizations like the Jewish National Fund, North Shore Animal League, and Lustgarten Foundation.

Key Points: 
  • Ali Weiss Jewelry extends their giving period throughout the year to support organizations like the Jewish National Fund, North Shore Animal League, and Lustgarten Foundation.
  • Ali Weiss Jewelry joined the Lustgarten Foundation when Ali, the Founder's, father-in-law, passed away from pancreatic cancer.
  • All our products are available in 14k yellow, rose, and white gold, where you can pick and choose as you wish to match your outfit and mood," said Ali Weiss, Founder of Ali Weiss Jewelry.
  • Ali Weiss Jewelry plans to expand their charity partnership throughout 2023, with the long-term goal of every piece providing a way to give back.

University Hospitals in Cleveland Enters into Master Purchase Agreement with ViewRay for Multiple MRIdian® Systems

Retrieved on: 
Thursday, January 5, 2023
Cancer, Prostate cancer, Pancreatic cancer, Radiation, Pancreas, Lung, NCI, Research, News, Irritation, Brain, Physics, Breast, Lustgarten Foundation for Pancreatic Cancer Research, Division, Prostate, Surgical oncology, University Hospitals Cleveland Medical Center, Bladder cancer, Nausea, Patient, Radiosurgery, 2021 Essex County Council election, Physician, Hair loss, U.S. News & World Report, Case Western Reserve University School of Medicine, Kidney, Fatigue, Hospital, Kidney cancer, Magnetic resonance imaging, Cryotherapy, Financial toxicity, Radiofrequency ablation, National Cancer Institute, Radiation therapy, Doctor of Philosophy, Liver, Spine, Medical imaging, Urology, Medicine

DENVER, Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University Hospitals (UH) Seidman Cancer Center in Cleveland has selected a MRIdian MR-Guided Radiation Therapy System as part of a master agreement for the purchase of up to four systems, and will be the first in Ohio at a research and teaching hospital to offer the precision of MRIdian's advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, kidney, gynecological, lung, liver, breast, brain, spine, and oligometastatic cancers.

Key Points: 
  • UH Seidman Cancer Center is part of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine.
  • "UH Seidman Cancer Center is at the forefront of clinical excellence and transformative innovation.
  • There was unanimous multi-disciplinary support to bring ViewRay's MRIdian MRI-guided radiotherapy to our center and provide our patients with the latest radiotherapeutic advancements.
  • We aim to continue the advancement of MR-guided adaptive radiotherapy through cutting-edge clinical trials and research to improve patient outcomes.